February 29, 2024~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty […]
Category: Uncategorized
FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT FROM PETRICHOR
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK®Which Occurred on September 20, 2022 ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, […]
FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ Research Triangle Park, NC, August 22, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; […]
Read More… from FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR
FENNEC PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF PEDMARK® (SODIUM THIOSULFATE INJECTION)
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate […]
FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action DateSet for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S. Commercialization of PEDMARKTM ~ Research Triangle Park, NC, August […]
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ ~ Funding to Support the Potential Commercialization of PEDMARKTM to Reduce the […]
Read More… from Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
Fennec Announces Results of Annual Meeting
Research Triangle Park, NC — (Marketwired) –June 14, 2022 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders […]
FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Research Triangle Park, NC, May 23, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor […]
Read More… from FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt Research Triangle Park, NC, May 12, […]
FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARKTM
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ Research Triangle Park, NC, April 27, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a unique formulation […]